Transgene Biotek logo

Transgene Biotek financials and balance sheet

BSE: 526139Healthcare ServicesSmall Cap

Last close ₹2.57up ₹0.20 (8.44%)

Share price at the BSE close on 23 Oct 2026. Previous close ₹2.37.

52-week range of traded prices to 23 Oct 2026
₹1.83Low, 4 Feb 2026₹4.34High, 23 Oct 2025
Market cap
₹19 Cr4,238th largest listed
P/E
Lossover the last 12 months
P/B
2.3
Dividend yield
Nonein the last 12 months
ROE
−17.5%
ROCE
−2.6%
Debt to equity
2.05
Volume, BSE
26,565

10 years at a glance

Standalone: the listed company alone, without its subsidiaries. ₹ crore, years to March.Transgene Biotek annual reports

Revenue, net profit and borrowings, ₹ crore

  • Revenue
  • Net profit
  • Borrowings
  • Loss
A loss in 9 of the 9 years with results on record

Operating and net margin, per cent

  • Operating margin
  • Net margin

The years either side of a change of basis do not compare. From the year to Mar 2019, the company's revenue for that year, ₹0.07 Cr, differs from its quarters added, ₹2.07 Cr.

Results for the year to Mar 2026

Standalone: the listed company alone, without its subsidiaries. ₹ crore.

From revenue to net profit

  1. Revenue0.2
  2. Employee costs−0.1
  3. Other expenses−0.6
  4. Operating profit−0.5
  5. Depreciation−0.2
  6. Other income+0.1
  7. One-off items0.0
  8. Finance costs−1.1
  9. Profit before tax−1.7
  10. Tax0.0
  11. Net profit−1.7

What the company owns

  • Plant, investments and other assets₹34 Cr
  • Cash and bank₹0 Cr
  • Inventory₹0 Cr

What pays for it: net worth and liabilities

  • Borrowings₹17 Cr
  • Other liabilities₹17 Cr
  • Owed to suppliers₹0 Cr

Profit and loss

Standalone, ₹ crore, years to March. No results on record for the year to Mar 2023.Transgene Biotek quarterly results

₹ croreMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Filed 20 JunMar 2023Mar 2024Filed 1 JulMar 2025Filed 10 JunMar 2026Filed 29 May
Revenue from operations0.30.10.10.00.20.1–0.20.30.2
–2.20.80.90.70.6–0.91.40.8
Materials and goods bought–0.00.00.00.10.0–0.00.00.0
Employee costs–0.3–0.30.20.3–0.30.30.1
Other expenses–1.8–0.60.40.3–0.51.10.6
Operating profit before depreciation–−2.1−0.7−0.9−0.5−0.5–−0.6−1.1−0.5
Operating margin–−1,784.2%−966.5%−21,590.0%−309.2%−535.5%–−256.3%−430.9%−257.3%
Materials, % of revenue–41.3%–370.0%35.8%−53.0%–0.3%0.0%0.0%
Employee costs, % of revenue–277.7%–7,237.5%144.6%332.1%–130.2%118.1%69.7%
Other expenses, % of revenue–1,565.4%–14,072.5%228.5%356.4%–225.8%412.8%287.6%
Depreciation and amortisation17.59.99.99.99.99.9–0.10.10.2
Operating profit after depreciation–−12.0−10.6−10.8−10.4−10.4–−0.7−1.2−0.7
Other income0.47.42.00.20.30.2–0.20.80.1
Finance costs–1.00.30.40.30.2–0.10.21.1
One-off items–––––0.0–0.00.00.0
Profit before tax−19.6−5.7−8.8−11.0−10.4−10.4–−0.7−0.7−1.7
Tax–0.8–––0.0–0.00.00.0
Net profit−19.6−6.4−8.8−11.0−10.4−10.4–−0.7−0.7−1.7
Net margin−6,039.4%−5,455.9%−12,384.5%−2,74,050.0%−6,137.1%−12,000.1%–−272.5%−259.3%−782.6%
Materials, employee costs and other expenses are shown for the years they add up to operating expenses; for the year to Mar 2019 they do not, so they are left blank. Operating expenses, operating profit before depreciation and operating profit after depreciation are left blank for the year to Mar 2017: the statement does not state its finance costs, which operating profit is worked out from, so operating profit is not given.
Earlier years, Mar 2008 to Mar 2016
₹ croreMar 2008Mar 2009Mar 2010Mar 2011Mar 2012Mar 2013Mar 2014Mar 2015Mar 2016
Revenue from operations3.73.74.010.026.315.01.00.30.3
2.02.12.48.225.115.92.52.01.3
Materials and goods bought0.30.30.65.922.813.80.20.0–
Employee costs0.30.40.40.41.1–1.01.20.7
Other expenses1.21.41.42.01.2–1.30.80.7
Operating profit before depreciation1.81.61.71.71.2−0.8−1.6−1.7−1.0
Operating margin47.4%42.2%41.6%17.3%4.5%−5.6%−159.9%−510.1%−284.7%
Materials, % of revenue9.1%8.1%14.3%58.9%86.7%–24.5%4.3%–
Employee costs, % of revenue8.3%10.4%9.1%3.7%4.4%–104.4%358.0%195.8%
Other expenses, % of revenue32.6%37.0%33.8%20.1%4.4%–131.1%247.7%189.4%
Depreciation and amortisation0.30.30.30.30.41.017.217.218.0
Operating profit after depreciation1.51.21.31.40.8−1.9−18.8−18.9−19.0
Other income0.0––0.02.90.10.8––
Finance costs0.30.80.70.70.60.20.00.30.0
Profit before one-off items and tax–0.40.60.73.1−2.0−18.0−19.2−19.0
One-off items–––−0.514.2––0.0–
Profit before tax1.10.40.60.217.3−2.0−18.0−19.2−19.0
Tax0.10.00.00.05.6––––
Net profit1.10.40.60.111.7−2.0−18.0−19.2−19.0
Net margin28.2%10.3%13.8%1.5%44.4%−13.2%−1,833.3%−5,768.5%−5,448.9%
Standalone, ₹ crore, years to March.

Balance sheet

Standalone, ₹ crore, at 31 March.

₹ croreMar 2022Filed 20 JunMar 2023Mar 2024Filed 1 JulMar 2025Filed 10 JunMar 2026Filed 29 May
−0.2–−6.9−7.6−9.2
Share capital75.8–75.875.875.8
Reserves−76.0–−82.6−83.3−85.0
12.0–14.014.517.1
9.1–11.012.613.1
28.3–28.329.129.8
Total assets37.2–32.434.233.8
36.5–31.332.932.7
0.7–1.11.21.0
Net debt12.0–14.014.217.1
Borrowings are counted again inside the liabilities due within a year and after a year. No balance sheet is on record for the years to Mar 2017, Mar 2018, Mar 2019, Mar 2020 and Mar 2021, so its lines and the ratios worked from it are blank there.

Cash flow

Standalone, ₹ crore, years to March.

₹ croreMar 2022Filed 20 JunMar 2023Mar 2024Filed 1 JulMar 2025Filed 10 JunMar 2026Filed 29 May
0.09–−0.571.20−0.01
0.09–−0.572.36−0.38
0.51–−0.142.700.01
Inventories−0.07–0.000.000.00
Payables−0.04–−0.031.390.00
Other working capital0.62–−0.111.310.01
Capital spending0.00–0.000.000.00
Free cash flow0.09–−0.571.20−0.01
Cash from investing−0.10–−0.18−1.700.15
0.00–0.750.78−0.36
Dividends paid0.00–0.000.000.00
Shares bought back0.00–0.000.000.00
Shares issued0.00–0.000.000.00
Net change in cash−0.01–0.010.28−0.22
Capital spending is part of cash from investing, and dividends paid, shares bought back and shares issued are part of cash from financing. Each is shown as an amount on a line of its own, and the section's other items are in its total only. No cash flow statement is on record for the years to Mar 2017, Mar 2018, Mar 2019, Mar 2020 and Mar 2021.

Per share

Standalone, ₹ per share, years to March.

₹ per shareMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Filed 20 JunMar 2023Mar 2024Filed 1 JulMar 2025Filed 10 JunMar 2026Filed 29 May
Earnings per share−₹2.59–−₹1.20−₹1.40−₹1.38−₹1.37––−₹0.09−₹0.22
Diluted earnings per share−₹2.59–−₹1.20−₹1.40−₹1.38−₹1.37––−₹0.09−₹0.22
Book value per share–––––−₹0.03–−₹0.91−₹1.00−₹1.21
Shareholder yield–––––0.0%–0.0%0.0%0.0%
Market cap at the year end (₹ crore)13.615.830.322.834.727.4–61.725.415.0
Earnings per share is left blank for the year to Mar 2018: the earnings per share stated does not match any profit the filing states over the shares in issue, and the share count barely moved during the period. Earnings per share is left blank for the year to Mar 2024: the earnings per share stated has the opposite sign to the profit stated beside it, so it is not shown.

Ratios

Standalone, years to March.Transgene Biotek PE ratio and valuation

RatioMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Filed 20 JunMar 2023Mar 2024Filed 1 JulMar 2025Filed 10 JunMar 2026Filed 29 May
Revenue growth−6.6%−63.7%–−94.4%4,150.0%−49.0%––9.1%−19.0%
–––––5,280.6%–9.5%9.4%19.7%
––––––––−0.1 pts10.4 pts
From the net margin––––––––−0.5 pts18.9 pts
From asset turnover––––––––0.6 pts−5.8 pts
From borrowing––––––––−0.2 pts−2.7 pts
Return on capital employed–––––−87.9%–−9.9%−17.5%−9.4%
Receivable days–––––0–000
Inventory days–––––−752–20,623––
Payable days–––––−1,612–1,23,553––
Cash conversion cycle, days–––––860–−1,02,930––
Working capital days–––––−4,968–−1,559−4,560−3,197
Asset turnover–––––0.00–0.010.010.01
Assets per rupee of net worth–––––−188.93–−4.72−4.61−4.05
Sales per rupee of plant–––––0.05–0.140.080.07
Capital spending to depreciation–––––0.00–0.000.000.00
Plant being built, % of plant in use–––––0.0%–0.0%0.0%0.0%
Interest cover is left blank for the years to Mar 2018, Mar 2019, Mar 2020, Mar 2021, Mar 2022, Mar 2024, Mar 2025 and Mar 2026: operating profit after depreciation is a loss, and a loss covers no interest bill. Revenue growth is left blank for the year to Mar 2019: between the two periods the company restated its earlier figures, so the two are on different bases and the change is not worked out. Debt to equity is left blank for the years to Mar 2022, Mar 2024, Mar 2025 and Mar 2026: net worth is below zero, so there is no shareholders' money to set the borrowings against. No balance sheet is on record for the years to Mar 2017, Mar 2018, Mar 2019, Mar 2020 and Mar 2021, so its lines and the ratios worked from it are blank there.

Growth and returns over 3, 5 and 10 years

Standalone: the listed company alone, without its subsidiaries. Each window ends with the year to Mar 2026.

Return on assets, latest year
−4.9%
Measure10 years5 years3 years
Revenue growth, yearly rate−4.9%4.4%–
Return on equity, average–1,329.8%12.9%
Return on capital employed, average–−31.2%−12.2%
Operating margin, average–−370.0%−314.8%
Net margin, average−35,264.6%−3,328.6%−438.1%
Asset turnover, average–0.010.01

Where the cash came from and went

Standalone: the listed company alone, without its subsidiaries. ₹ crore, added up over each window, which ends with the year to Mar 2026.

₹ crore3 yearsLatest year
Cash from operations0.62−0.01
Cash from investing−1.720.15
Cash from financing1.17−0.36
Capital spending0.000.00
Dividends paid0.000.00
Shares bought back0.000.00
Shares issued for cash0.000.00
Borrowings raised7.450.70
Borrowings repaid4.980.00